Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie raka piersi lub płuc
- •Nowe ogniska przerzutów do opon mózgowych potwierdzone wynikami badań (dodatni wynik płynu mózgowo-rdzeniowego lub typowe objawy widoczne na zdjęciach)
- •Kwalifikacja do radioterapii
- •Wiek co najmniej 18 lat
- •Zdolność finansowa do leczenia terapią protonową
- •Ocena stanu ogólnego co najmniej 60 punktów
- •Hemoglobina co najmniej 8,0 g/dl
- •Liczba płytek krwi co najmniej 100 000/mm³
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Dodatni wynik testu ciążowego (w ostatnich 14 dni)
- •Zbyt wysokie wartości bilirubiny (powyżej 1,5 normy)
- •Zbyt wysokie wartości enzymów wątroby (powyżej 3 normy)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (58)
Mayo Clinic Hospital in Arizona
Phoenix, United States
University of Arkansas for Medical Sciences
Little Rock, United States
UC San Diego Health System - Encinitas
Encinitas, United States
UC San Diego Moores Cancer Center
La Jolla, United States
UC San Diego Medical Center - Hillcrest
San Diego, United States
California Protons Cancer Therapy Center
San Diego, United States
Sibley Memorial Hospital
Washington D.C., United States
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
UM Sylvester Comprehensive Cancer Center at Doral
Doral, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
Miami Cancer Institute
Miami, United States
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, United States
Alton Memorial Hospital
Alton, United States
Northwestern University
Chicago, United States
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, United States
Northwestern Medicine Cancer Center Delnor
Geneva, United States
Memorial Hospital East
Shiloh, United States
Northwestern Medicine Cancer Center Warrenville
Warrenville, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Cancer Center-Overland Park
Overland Park, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Wayne State University/Karmanos Cancer Institute
Detroit, United States
Weisberg Cancer Treatment Center
Farmington Hills, United States
McLaren Cancer Institute-Flint
Flint, United States
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, United States
Mayo Clinic in Rochester
Rochester, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
University of Kansas Cancer Center - North
Kansas City, United States
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, United States
Mercy Hospital Springfield
Springfield, United States
Washington University School of Medicine
St Louis, United States
Mercy Hospital South
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, United States
Memorial Sloan Kettering Monmouth
Middletown, United States
Memorial Sloan Kettering Bergen
Montvale, United States
NYU Langone Hospital - Brooklyn
Brooklyn, United States
Memorial Sloan Kettering Commack
Commack, United States
Memorial Sloan Kettering Westchester
Harrison, United States
NYU Langone Hospital - Long Island
Mineola, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, United States
New York Proton Center
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Montefiore Medical Center-Einstein Campus
The Bronx, United States
Montefiore Medical Center - Moses Campus
The Bronx, United States
Memorial Sloan Kettering Nassau
Uniondale, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, United States
Inova Alexandria Hospital
Alexandria, United States
Inova Schar Cancer Institute
Fairfax, United States
Inova Fair Oaks Hospital
Fairfax, United States
Inova Loudoun Hospital
Leesburg, United States
Trial contact
Site Public Contact
Eric Lehrer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Fen Xia
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jona A. Hattangadi-Gluth
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Carmen Kut
PRINCIPAL_INVESTIGATOR
Site Public Contact
Morgan Freret
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Matthew D. Hall
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nikhil Rammohan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Vinai Gondi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Danielle Cunningham
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Brian K. Yeh
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Jay W. Carlson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Yao Yu
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jonathan T. Yang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Arpit M. Chhabra
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jana L. Fox
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joshua D. Palmer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jerry J. Jaboin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rachna Malani
PRINCIPAL_INVESTIGATOR
Site Public Contact
Avani D. Rao
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.